The Substance Abuse Treatment to HIV Care II (SAT2HIV-II) Project
SAT2HIV-II
1 other identifier
interventional
428
1 country
1
Brief Summary
An experiment to test the effectiveness of providing monetary bonuses to staff for achieving pre-defined performance targets regarding the implementation of a motivational interviewing-based brief intervention for substance use.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2021
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 18, 2020
CompletedFirst Posted
Study publicly available on registry
December 29, 2020
CompletedStudy Start
First participant enrolled
January 14, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2023
CompletedResults Posted
Study results publicly available
May 14, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2026
ExpectedNovember 13, 2025
October 1, 2025
2.3 years
December 18, 2020
May 6, 2024
October 29, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
Staff-level Implementation Consistency
The cumulative number of brief interventions that each HSO staff participant implemented with HSO client participants during the implementation phase.
Assessed at the end of month 12
Staff-level Implementation Quality
The cumulative sum quality score that each HSO staff participant demonstrated during the implementation phase. Each motivational interviewing brief intervention (MIBI) is rated on a scale from 0 (zero quality) to 12 (highest quality possible). Each individual MIBI quality score is summed to create a cumulative sum quality score. Higher scores indicated higher quality (i.e. motivational interviewing fidelity). The lower limit is zero. There is not an upper limit.
Assessed at the end of month 12
Secondary Outcomes (2)
Staff-level Average Change (Follow-up Minus Baseline) in Their Client Participant's Days Using Primary Substance
Assessed at 4-weeks from the baseline assessment
Staff-level Average Change (Follow-up Minus Baseline) in Their Client Participant's Generalized Anxiety Disorder 7-item (GAD-7) Score
Assessed at 4-weeks from the baseline assessment
Study Arms (4)
Facilitation, Training, Feedback, and Consultation (FTFC) Staff
ACTIVE COMPARATORA multilevel implementation strategy
Facilitation, Training, Feedback, Consultation, and Incentivization (FTFCI) Staff
EXPERIMENTALAn enhanced version of the multilevel implementation strategy
Facilitation, Training, Feedback, and Consultation (FTFC) Clients
ACTIVE COMPARATORClients served within the context of a multilevel implementation strategy
Facilitation, Training, Feedback, Consultation, and Incentivization (FTFCI) Clients
EXPERIMENTALClients served within the context of an enhanced multilevel implementation strategy
Interventions
A multilevel implementation strategy that includes team-focused facilitation, as well as staff-focused training, feedback, and consultation
A multilevel implementation strategy that includes team-focused facilitation, as well as staff-focused training, feedback, consultation, and incentivization.
Eligibility Criteria
You may qualify if:
- + years of age
- + years of age
- Diagnosed with HIV
You may not qualify if:
- None
- \* None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ohio State Universitylead
- National Institute on Drug Abuse (NIDA)collaborator
Study Sites (1)
The Ohio State University
Columbus, Ohio, 43210, United States
Related Publications (3)
Garner BR, Bouris A, Charlebois ED, Li DH, Dakin A, Moskowitz J, Benbow N, Christopoulos K, Hickey MD, Imbert E. The Strategies Timeline and Activities Reporting Tables: Improving HIV Care by Improving the Reporting of Implementation Strategies. J Acquir Immune Defic Syndr. 2025 Apr 15;98(5S):e205-e215. doi: 10.1097/QAI.0000000000003613.
PMID: 40163072DERIVEDGarner BR, Tueller SJ, Bradshaw M, Speck KJ, Satre D, Rash C, Donohoe T, Mungo J, Philbrick S, Ruwala R, Roosa MR, Zehner M, Ford JH 2nd. Testing the incremental effectiveness of pay-for-performance to improve implementation of a motivational interviewing brief intervention for substance use disorders in HIV settings: Results of a parallel cluster-randomized type 3 hybrid trial. Res Sq [Preprint]. 2024 Aug 9:rs.3.rs-4614222. doi: 10.21203/rs.3.rs-4614222/v1.
PMID: 39149465DERIVEDGarner BR, Tueller S, Bradshaw M, Speck K, Satre D, Rash C, Donohoe T, Mungo J, Philbrick S, Ruwala R, Roosa M, Zehner M, Ford J 2nd. Testing the incremental effectiveness of pay-for-performance to improve implementation of a motivational interviewing brief intervention for substance use disorders in HIV settings: Results of a cluster-randomized type 3 hybrid trial. Res Sq [Preprint]. 2023 Dec 20:rs.3.rs-3685134. doi: 10.21203/rs.3.rs-3685134/v1.
PMID: 38196639DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Dr. Bryan R. Garner
- Organization
- The Ohio State University
Study Officials
- PRINCIPAL INVESTIGATOR
Bryan R Garner, PhD
Ohio State University
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Masking Details
- Single blind masking
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
December 18, 2020
First Posted
December 29, 2020
Study Start
January 14, 2021
Primary Completion
April 30, 2023
Study Completion (Estimated)
May 31, 2026
Last Updated
November 13, 2025
Results First Posted
May 14, 2025
Record last verified: 2025-10
Data Sharing
- IPD Sharing
- Will share
- Time Frame
- After study completion
- Access Criteria
- Anyone who wishes to access the data.
After deidentification, all of the individual participant data collected during the trial.